Formulation: A solid
Formal Name: 4-[[5-amino-1-[(3-methyl-2-thienyl)carbonyl]-1H-1,2,4-triazol-3-yl]amino]-N-[2-[[1-[2-[2-[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]ethoxy]ethoxy]ethyl]-1H-1,2,3-triazol-4-yl]methoxy]ethyl]-benzenesulfonamide
Purity: ≥98%
Formula Markup: C38H42N12O10S2
Formula Weight: 890,9
Shelf life (days): 1460
CAS Number: 2756741-90-7
Notes: CPS2 is a proteolysis-targeting chimera (PROTAC) composed of the Cdk2 binder J2, a derivative of the Cdk and Aurora kinase inhibitor JNJ-7706621 (Item No. 18494), connected to the cereblon inhibitor pomalidomide (Item No. 19877) by a linker region.{51687} It selectively degrades Cdk2 (IC50 = 24 nM) over seven additional CDKs at 500 nM but also degrades Aurora A kinase and Ikaros family zinc finger protein 1 (IKZF1) at 250 nM. CPS2 reduces Cdk2 levels and increases the percentage of cells expressing CD11b, a marker of differentiation, in primary acute myeloid lymphoma (AML) cells. It also decreases proliferation without reducing the viability of, as well as induces differentiation in, primary hematopoietic stem cells (HSCs).
English
Deutsch
